Co-targeting SOS1 enhances the antitumor effects of KRAS ^G12C inhibitors by addressing intrinsic and acquired resistance.

Autor: Thatikonda V; Boehringer Ingelheim RCV, Vienna, Austria. vthatikonda@exscientia.co.uk.; Exscientia, Vienna, Austria. vthatikonda@exscientia.co.uk., Lyu H; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jurado S; Boehringer Ingelheim RCV, Vienna, Austria., Kostyrko K; Boehringer Ingelheim RCV, Vienna, Austria., Bristow CA; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Albrecht C; Boehringer Ingelheim RCV, Vienna, Austria., Alpar D; Boehringer Ingelheim RCV, Vienna, Austria., Arnhof H; Boehringer Ingelheim RCV, Vienna, Austria., Bergner O; Boehringer Ingelheim RCV, Vienna, Austria., Bosch K; Boehringer Ingelheim RCV, Vienna, Austria., Feng N; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gao S; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gerlach D; Boehringer Ingelheim RCV, Vienna, Austria., Gmachl M; Boehringer Ingelheim RCV, Vienna, Austria., Hinkel M; Boehringer Ingelheim RCV, Vienna, Austria., Lieb S; Boehringer Ingelheim RCV, Vienna, Austria., Jeschko A; Boehringer Ingelheim RCV, Vienna, Austria., Machado AA; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Madensky T; Boehringer Ingelheim RCV, Vienna, Austria., Marszalek ED; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Mahendra M; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Melo-Zainzinger G; Boehringer Ingelheim RCV, Vienna, Austria., Molkentine JM; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jaeger PA; Boehringer Ingelheim RCV, Vienna, Austria., Peng DH; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Schenk RL; Boehringer Ingelheim RCV, Vienna, Austria., Sorokin A; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Strauss S; Boehringer Ingelheim RCV, Vienna, Austria., Trapani F; Boehringer Ingelheim RCV, Vienna, Austria., Kopetz S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Vellano CP; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Petronczki M; Boehringer Ingelheim RCV, Vienna, Austria., Kraut N; Boehringer Ingelheim RCV, Vienna, Austria., Heffernan TP; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Marszalek JR; Translational Research to Advance Therapeutics and Innovation in Oncology (TRACTION) Platform, Therapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pearson M; Boehringer Ingelheim RCV, Vienna, Austria., Waizenegger IC; Boehringer Ingelheim RCV, Vienna, Austria., Hofmann MH; Boehringer Ingelheim RCV, Vienna, Austria. marco.hofmann@boehringer-ingelheim.com.

Publikováno v: Nature cancer [Nat Cancer] 2024 Sep; Vol. 5 (9), pp. 1352-1370. Date of Electronic Publication: 2024 Aug 05.